Regencell Bioscience Plans To Sell Up To $500M In Stock Over Time

Regencell Bioscience Holdings Limited (NASDAQ: RGC) has filed a prospectus supplement with the SEC to potentially sell up to $500 million of its ordinary shares through an at-the-market equity offering program. The company has engaged Univest Securities, LLC as its sales agent for this offering. Proceeds from the sales will primarily be used for working capital, capital expenditures, and general corporate purposes, although the company is not obligated to sell any shares under this program.